C hronic myeloid leukemia (CML)i sac ancero fh ematopoietics temc ells.I tr epresentsa pproximately2 0% of adultl eukemia diagnoses 1 anda ffectsa pproximately1 per100,000 malesand 0.6/0.7per 100,000 femalesinthe United States. 2 Although thee tiology of CMLi sp oorlyu nderstood, it is cleart hatc ertain environmentale xposures can induce the disease. Benzenee xposure has been connected with development of variousleukemias, includingCML. 3 The Environmental ProtectionAgencyhas regulated benzeneexposure, labeling it as acarcinogenand restrictingits u se;however,benzene is foundin many materials, includingp lastics, rubber,and cigarettesmoke, making it difficult to control. Cigarettes moke,i np articular, also is associated with increases in myeloid leukemias, as well as increased diseasep rogressionf or CML. 4 Ionizing radiation wasimplicated when cohortsofJa panese survivorsofthe atomic bombsdeveloped CML, alongwithacute myelogenousleukemia anda cute lymphoblasticl eukemia. 5 The mechanismsb yw hich thesee nvironmental exposuresl eadt oC ML arep oorlyu nderstood.
CMLi sn otable because it represents thef irst cancer to be associated with as pecificc hromosomala bnormality.I n 1960,N owella nd Hungerford reported thatw hite blood cellsd erivedf romp atientsw ithC ML consistently showed thep resenceo fas mall aberrant chromosome,t ermedt he Philadelphia chromosome (Ph). 6 This aberrant chromosome wastracedbacktothe stem cellsofindividualswithCML and wasi nstrumentali ne stablishinga ssaysf or monitoring disease and, ultimately,the first-line therapiesusedtoday.Itwas realizedthatthe Ph wascausedbyatranslocation of chromo-somes9and 22.1Whenthe breakpointsweremapped,itwas discovered thatan ew protein, BCR-ABL, wasf ormedf rom thejoiningofthe 2chromosomes. ExpressionofBCR-ABL in cell culturewas foundtobesufficientfor transformation, and thus BCR-ABLw as identified as thep utative cause of CML. Today, we use measureso fB CR-ABL proteina nd mRNA as sensitive assays fordisease.Drugs thatb lock BCR-ABLfunction have been developed, andt hese have proven so efficaciousthatwithin af ew yearso ftheir introduction,theyhave The symposiumo penedw itha no verviewo fC ML by Jolynn Sessions.S he coveredt he diagnosisc riteriaf or CML anddiscussed them olecular pathogenesis mediated by BCR-ABL. Detailso ft he translocation of chromosomes9a nd 22 were described, alongw itht he consequenceso fb reakpoint variationf or disease.S he coveredt he clinicalc ourseo ft he disease, observingw henB CR-ABL inhibitors arem oste ffective.S he describedt ests used to measured isease,i ncluding thec osts associated with each;t hese testsi ncluded hematologic, cytogenetic,a nd polymerasec hain reaction assays. Sessions also compared therelativesensitivities of each assay andp resented theu se anda ppropriate pointt oe mploye ach assay.
Christopher Fausel continuedw ith ad iscussiono fi matinib, thecurrentfront-lineCML therapy, whichfunctions by inhibitingBCR-ABL.T akingahistoricalapproach, he opened with ad escription of earlyf orms of chemotherapyu sedt o treat CML, beginningwithbusulfan andhydroxyurea,which were replaced by interferon ∂ with or withoutcytarabine. He then listed theefficacyand adverse effectso fthese therapies. He also discussedb onem arrowt ransplanta nd weighed thep ossibility of cure againstt he significantp ossibility of mortalityand adverse effectsfromthe transplantf or thesurvivors.T he mechanism of action forimatinibw as explained, followed by areviewofdifferentclinicaltrialsand theresults. Finally, Fausel coveredt he need to monitori matinib-treated patients with CML, both foradverse effectsand forthe rising imatinib-resistantclones.
The symposiume ndedw ithap resentationb yD avid Frame, in whichh ed iscussed imatinibr esistancea nd outlinedm echanismsb yw hich it mighta rise ands trategiesf or avoidingi t. He delineated 5p otentialm echanismsb yw hich cancer cellsc an become resistantt oi matinib: (1)i ncreased plasma proteins thatb indt oimatinib, (2)increased efflux of imatinibthrough active transporters,( 3) thearising of mutationsi nB CR-ABL thatb lock thea bility of imatinibt ob ind, (4)the arisingofmutations in theSrc pathway, an alternative meanso fp romotingt he transformed phenotype, and( 5) the
